MedTrace Logo

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

NCT05513612 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-03-01

No results posted yet for this study

Summary

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with hematopoietic and lymphoid malignancies.

Conditions

  • Acute Myeloid Leukemia (AML)
  • B-cell Non-Hodgkin's Lymphoma (B-NHL)
  • Multiple Myeloma (MM)
  • T-Cell Leukemia/Lymphoma, Adult
  • B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

BIOLOGICAL

Autologous CAR-T cells

CAR-T cells will be infused intravenously.

DRUG

Fludarabine

Administered according to package insert

DRUG

Cyclophosphamide

Administered according to package insert

Sponsors & Collaborators

  • UTC Therapeutics Inc.

    collaborator INDUSTRY

  • Shanghai Pudong Hospital

    lead OTHER

Principal Investigators

  • Zhiguo Long · Shanghai Pudong Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05513612 on ClinicalTrials.gov